key: cord-1051773-sm1bofpp authors: Liu, Jia; Yang, Wei; Liu, Yue; Lv, Cheng; Ruan, Lianguo; Zhao, Chen; Huo, Ruili; Shen, Xin; Miao, Qing; Lv, Wenliang; Li, Hao; Shi, Huaxin; Hu, Lijie; Yang, Zhixu; Zhang, Li; Wang, Bing; Dong, Guoju; Xian, Yongyue; Li, Bin; Zhou, Zhenqi; Xu, Chunyan; Chen, Yingying; Bian, Yongjun; Guo, Jing; Yang, Jinliang; Wang, Jian; Qi, Wensheng; Chen, Suping; Chen, Yang; Yan, Bei; Wang, Wei; Li, Jing; Xie, Xiaolei; Xu, Ming; Jiang, Jianxin; Wang, Gang; Cong, Xiaodong; Zhu, Haoning; Shi, Jiaheng; Leng, Luxing; Li, Dongxu; Guo, Lanping; Huang, Luqi title: Combination of Hua Shi Bai Du Granule (Q-14) and Standard Care in the Treatment of Patients with Coronavirus Disease 2019 (COVID-19): A Single-center, Open-label, Randomized Controlled Trial date: 2021-07-17 journal: Phytomedicine DOI: 10.1016/j.phymed.2021.153671 sha: 0292cbf9970429642f50640938c419e027e5ac81 doc_id: 1051773 cord_uid: sm1bofpp OBJECTIVE: : To evaluate the efficacy and safety of Hua Shi Bai Du Granule (Q-14) plus standard care compared with standard care alone in adults with coronavirus disease (COVID-19). STUDY DESIGN: : A single-center, open-label, randomized controlled trial. SETTING: : Wuhan Jinyintan Hospital, Wuhan, China, February 27 to March 27, 2020. PARTICIPANTS: : A total of 204 patients with laboratory-confirmed COVID-19 were randomized into the treatment group and control group, consisting of 102 patients in each group. INTERVENTIONS: : In the treatment group, Q-14 was administered at 10 g (granules) twice daily for 14 days, plus standard care. In the control group, patients were provided standard care alone for 14 days. MAIN OUTCOME MEASURE: : The primary outcome was the conversion time for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral assay. Adverse events were analyzed in the safety population. RESULTS: : Among the 204 patients, 195 were analyzed according to the intention-to-treat principle. A totalof 149 patients (71 vs. 78 in the treatment and control groups, respectively) tested negative via the SARS-CoV-2 viral assay. There was no statistical significance in the conversion time between the treatment group and control group (full analysis set: median (interquartile range): 10.00 (9.00-11.00) vs. 10.00 (9.00-11.00); mean rank: 67.92 vs. 81.44; P=0.051.). The recovery time for fever was shorter in the treatment group than in the control group. The disappearance rate of symptomslike cough, fatigue, and chest discomfort was significantly higher in the treatment group. In chest computed tomography (CT) examinations, the overall evaluation of chest CT examination after treatment compared with baseline showed that more patients showed improvement in the treatment group. There were no significant differences in the other outcomes. CONCLUSION: : The combination of Q-14 and standard care for COVID-19 was useful for the improvement of symptoms (such as fever, cough, fatigue, and chest discomfort), but did not result in a significantly higher probability of negative conversion in the SARS-CoV-2 viral assay. No serious adverse events were observed. TRIAL REGISTRATION: : ChiCTR2000030288 In the treatment group, Q-14 was administered at 10 g (granules) twice daily for 14 days, plus standard care. In the control group, patients were provided standard care alone for 14 days. The primary outcome was the conversion time for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral assay. Adverse events were analyzed in the safety population. Among the 204 patients, 195 were analyzed according to the intention-to-treat principle. A totalof 149 patients (71 vs. 78 in the treatment and control groups, respectively) tested negative via the SARS-CoV-2 viral assay. There was no statistical significance in the conversion time between the treatment group and control group (full analysis set: median (interquartile range): 10.00 (9.00-11.00) vs. 10.00 (9.00-11.00); mean rank: 67.92 vs. 81.44; P=0.051.). The recovery time for fever was shorter in the treatment group than in the control group. The disappearance rate of symptomslike cough, fatigue, and chest discomfort was significantly higher in the treatment group. In chest computed tomography (CT) examinations, the overall evaluation of chest CT examination after treatment compared with baseline showed that more patients showed improvement in the treatment group. There were no significant differences in the other outcomes. The combination of Q-14 and standard care for COVID-19 was useful for the improvement of symptoms (such as fever, cough, fatigue, and chest discomfort), but did not result in a significantly higher probability of negative conversion in the SARS-CoV-2 viral assay. No serious adverse events were observed. The coronavirus disease pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in considerable morbidity and mortality in more than 200 countries. It has become a major public health crisis on a global scale . Information regarding the epidemiology and clinical features of COVID-19 Chen et al., 2020) provides good support for its clinical prevention and treatment, but many of the drugs previously hailed as star drugs, such as remdesivir, favipiravir, lopinavir-ritonavir, and chloroquine or hydroxychloroquine have not shown ideal results in clinical trials, and some of them have been found to have obvious toxic side effects Tang et al., 2020) . Scientists around the world are actively seeking potentially effective drugs or developing vaccines to treat COVID-19. Widespread use of the vaccine has been important in halting the spread of COVID 19, but the number of cases worldwide continues to rise due to a lack of vaccine capacity and the mutation of the virus. There is still a long way to go to develop effective drugs for COVID-19. China has quickly halted the spread of COVID-19 with strong containment measures . The strategy of integrated Traditional Chinese Medicine (TCM) with western medicine plays an important role in the prevention and control of COVID-19 in China, with more than 90% of confirmed cases receiving TCM therapy (SCIO-China, 2020 (Tang, 2006) . At the critical moment of the COVID-19 outbreak in Wuhan, China, we conducted a single-center, open-label, randomized controlled trial to assess the efficacy and safety of Q-14 in hospitalized adults with laboratory-confirmed COVID-19. In this open-label randomized trial, we recruited patients with COVID-19 from the We recruited 204 patients with laboratory-confirmed COVID-19 at the Wuhan Jinyintan Hospital between February 27 and March 27, 2020. The inclusion criteria were as follows:1) compliance with the diagnostic criteria for general type COVID-19 in the NHC-NATCM-China guidelines (version 6.0); 2) 18≤ aged ≤75 years; 3) Acceptance to participate in the trial by the patient, the legal guardian, or the person in charge of the medical institution signed the informed consent through a paper signature. The exclusion criteria included: 1) critical patients; 2) patients who could not guarantee compliance of using Q-14 during the treatment period, or patients who The primary outcome of this trial was the conversion time of the SARS-CoV-2 viral assay. The secondary outcomes were: 1) the change inthe 7-point scale, 2) the rate of critical aggravation 3) blood routine test outcomes 4) blood biochemical test outcomes 5) recovery time for fever 6) symptom improvement,and 7) evaluation of chest CT examination after treatment compared with baseline. Adverse events were reviewed daily to ensure patient safety. SARS-CoV-2 viral assays for specimens from the upper respiratory tract were performed on days 0 and 7 to 15. If the test result was negative, the SARS-CoV-2 viral assay was conducted at least 24 hours later to ensure that there were two consecutive reports of negative results. When there were two consecutive negative results, the patient was defined as a conversion-of-negative ending, and the day of the first negative report was determined as the conversion day. The time from day 0 to the day of conversion was defined as the conversion time. The 7-point scale was a seven-category ordinal scale to test the condition and prognosis of severity during treatment. It consisted of the following categories: 1) not hospitalized with the resumption of normal activities; 2) not hospitalized,but unable to resume normal activities; 3) hospitalized, not requiring supplemental oxygen; 4) hospitalized, requiring supplemental oxygen; 5) hospitalized, requiring nasal high-flow oxygentherapy, noninvasive mechanical ventilation, orboth; 6) hospitalized, requiring extracorporeal membrane oxygenation, invasivemechanical ventilation, or both; and 7) death.The 7-point scale was recorded from day 1 to 14. The change inthe 7-point scale was the score difference after treatment compared with baseline. The classification of COVID-19 was recorded on days 0, 1,and 14. The classification included four categories: mild, moderate, severe, and critical, in increasing severity. If the classification changed to critical during days 1 to 14, the patient was defined as having critical aggravation. The rate of critical aggravation was assessed after treatment. Routine blood tests and blood biochemical test outcomes included: complete blood cell count with differential, blood chemistry, creative protein, hypersensitive C-reactive protein, amyloid protein, myohemoglobin, hypersensitive troponin, erythrocyte sedimentation rate, ferroprotein, D-dimer, and interleukin 6, which were tested on days 0, 7, and 14. Vital signs were recorded on days 0, 1,and 14. If the body temperature was > 37.3°Cthe patient was considered to have a fever. We recorded the day when it began to remain stable (below 37.3°C) in order to determinethe fever recovery time. Symptoms including cough, fatigue, headache, chest discomfort, and sore throat were recorded on days 0 and 14.The disappearance of symptoms was recorded after treatment. Symptom improvement was evaluated based on the disappearance rate of the five symptoms. Chest computed tomography (CT) examinations were performed on days 0 and 14. Two radiologists with at least 20 years of working experience reviewed the CT reports and images, who were unaware of the randomization. The judgment of chest CT included: 1) score of ground glass area; 2) score of consolidation area; 3) density change of ground glass imaging manifestation; 4) density change of consolidation imaging manifestation; 5) overall evaluation of chest CT examination after treatment compared with baseline. To count the score of the lesion area, each lung was divided into 10 regions according to anatomy, with 20 regions for both sides. If the lesion area was over 50% (contained) in one region, it was judged as 2 points, and if it was below 50%, it was judged as 1 point. The range of scores for the area ranged from 0 to 40 points. Density change was recorded after treatment as decreased, no change, or increased. The overall evaluation of chest CT examination was the case and proportion of improved, no-change, and aggravated patients in each group. In this trial, we recorded the timing, duration, severity, management, and consequences of adverse events, and determined their association with the use of study medications. (Annex 1) The sample size was calculated based on the alternative hypothesis that the hazard ratio of SARS-CoV-2 viral assay negative conversion rate between the treatment and control groups during the 14-day trial period was . It was assumed that the SARS-CoV-2 viral assay-negative conversion time followed an exponential distribution. We assumed that the SARS-CoV-2 viral assay negative conversion rate was 0.6, in all patients within 14 days, and the hazard ratio based on the experience of treatment at the time. The sample size distribution between the treatment and control groups was 1:1, the one-sided superiority type I error was 0.05, and the type II error was 0.2, that is, the power was 80%. We estimated a total sample size of 204 patients with adropout rate of 15%. For the primary outcome, the SARS-CoV-2 viral assay negative conversion time, we first used the Wilcoxon rank-sum test to test the difference in SARS-CoV-2 viral assay negative conversion time between the treatment group and control group and presented the medians and interquartile range (IQR). The Kaplan-Meier method was used to estimate the cumulative negative conversion rate and to draw the survival curve.The negative conversion rate was compared among groups using the log-rank test, and the median time and 95% confidence interval (CI) were calculated. The hazard ratios were estimated using the Cox regression model. Hazard ratios greater than 1 indicated that the negative conversion rate of the treatment group was higher than that of the control group. For secondary outcomes, the change inthe 7-point scale was tested using the Wilcoxon rank-sum test. The rate of critical aggravation was tested using Pearson's chi-square test. Both blood routine and blood biochemistry outcomes were numerical data, which were tested by the t-test for normal distribution data and Wilcoxon rank-sum test for non-normal distribution data. Fever recovery time was tested using the Wilcoxon rank-sum test. For symptom improvement, which indicated the disappearance rate of cough, chest tightness, headache, fatigue, and pharynx, we used the Pearson chi-square test. For the chest CT outcome, the score of area and density for both ground glass and consolidation imaging manifestations, and overall evaluation of chest CT examination, were tested using the Wilcoxon rank-sum test. Safety analyses were based on patients' actual exposure to the treatment. In this =2  study, statistical packages base, Stats, Rcompanion, and survival in R version-3.6.2,and SPSS 20.0, were used for statistical analyses and verifications. No patients were involved in the research design or implementation plan. There is no plan to disseminate the results of this trial to the study participants. Figure 4) . The change in the 7-point scale was similar between the two groups (median [ICQ]: FAS: -2.00[-3.00-0.00] vs. -2.00[-3.00-0.00], P=0.109). PPS: -2.00(-3.00, 0.00) vs. -2.00(-3.00, 0.00), P=0.232). No patient turned to the critical category during the observation. There was no significant difference in blood routine test and blood biochemical test. Fever recovery time was shorter in the treatment group than in the control group At present, there is no definite antiviral drug to accelerate the probability of negativeconversion for SARS-CoV-2 (Parvathaneni and Gupta, 2020; Yadav et al., 2020) , and the development of a vaccine (Torreele, 2020; appears to be the last straw for the prevention and control of COVID-19. The development of new antivirals requires considerable time and effort for drug design and validation. Clearly, not only will this take time, but everything is unknown. Administration of Huashi Baidu granule (Q-14) did not result in a significantly higher probability of negative conversion than the standard of care alone in patients admitted to hospital with COVID-19. However, it is beneficial for the improvement of typical symptoms in COVID-19 patients. Improvement in clinical symptoms is important to reduce the level of discomfort in hospitalized adult patients with COVID-19. Thus, relieving depression or anxiety caused by typical symptoms of COVID-19 patients or medical workers (Elhadi et al., 2020; such as fever, cough, fatigue, and chest discomfort is beneficial. Why Q14 can relieve some symptoms but not others is also one of the research directions that we need to focus on in the future. According to the theory of traditional Chinese medicine, the compatibility of the constituent drugs of Q14 plays a wonderful and important role, which may be one of the important basis for the optimization of prescription in the future. In our study, the safety of Huashi Baidu granule (Q-14) was investigated. No serious adverse events were reported, except for diarrhea (8 cases in the treatment group) or other adverse reactions in some patients, which resolved within a few days. The overall clinical safety of a 14-day course of Huashi Baidu granule (Q-14) administration is documented. On the other hand, we performed a subgroup analysis, an increase in the probability of negative conversion of SARS-CoV-2 viral assay conferred by the addition of a 14-day course of Huashi Baidu granule (Q-14) administration to the standard care in hospitalized adult patients with COVID-19 and cardiovascular diseases. Although the results were statistically significant, they were not particularly significant in terms of time (days). This is not within our expectations, which is an interesting finding. Although we cannot rule out the possibility of a chance finding, we think it may be pre-existing cardiovascular diseases experience disproportionately worse mortality outcomes Golemi et al., 2020) , and the findings of this clinical study may provide an effective drug for the prevention and treatment of COVID-19 patients with hypertension. More rigorous clinical and basic research is needed to validate this speculation. Chest CT is used for the diagnosis of COVID-19, as an important complement to the reverse-transcription polymerase chain reaction (RT-PCR) tests (Ai et al., 2020; Wong et al., 2020) . In the early stages of the COVID-19 disease, chest CT may havea greater diagnostic value than RT-PCR tests. At the same time, it will be a very important observational indicator to evaluate the curative effect ofthe therapeutic schedule. Inaddition, scientists have proposed a non-invasive and quantitative prognostic tool for predicting poor outcomes in patients with COVID-19 based on CT . Our study found that after 14 days of treatment, Huashi Baidu granule (Q-14) with standard care can significantly improve abnormal chest CT changes in COVID-19 patients and significantlydecrease the score of the ground glass area (characteristic chest CT change of . This result suggests that Huashi Baidu granule (Q-14) has an important therapeutic role in alleviating the condition of COVID-19 patients. Clinical evidence has shownthat TCM plays a significant role in the prevention and control of COVID-19 Xiao et al., 2020; Xiong et al., 2020) . Although these studies showed that TCM does not have a direct antiviral effect in clinical practice, its ability to quickly relieve clinical symptoms may be closely related to the enhancement of the immune ability of the body. The present study had some limitations. First, we did not set up a placebo as a Huashi Baidu granule (Q-14) control. In the context of the COVID-19 early outbreak in Wuhan, China, many clinical trials related to COVID-19 are yet to be prepared because of Wuhan quarantine, especially for the Huashi Baidu granule (Q-14) placebo. As we did not adopt stratification randomization according to disease severity, the cases of severe patients showed significant differences between the two groups. This may have greatly influenced the conclusions of this trial, and the placebo effect of Huashi Baidu granule (Q-14) cannot be ruled out. Second, the open-label rather than double-blind design may have resulted in the possibility of biased assessments. Third, we began to determine SARS-CoV-2 RNA conversion from the 7th day of the intervention, which may have overlooked some patients who hada negative conversion of SARS-CoV-2 within 7 days. Finally, the specimens collected in our trial for SARS-CoV-2 RNA determination were mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which could result in false-negative results. The global introduction of TCM is a demand forthetimes, which is anurgent worldwide demand for TCM. This trial provides evidence to support a notable improvement in typical uncomfortable symptoms caused by COVID-19 such as fever, cough, fatigue, and chest discomfort. Additionally, there was a significant improvement inchest CT by the addition of a 14-day course of Huashi Baidu granule LG contributed to finalize the structure of this paper. LH organized the research group and contributed to the overall designing and management of this trialfor the corresponding authorship. All data were generated in-house, and no paper mill was used. All authors agree to be accountable for all aspects of work ensuring integrity and accuracy. Wu contributed to the CT review data verifying. Hui Li contributed to the active ingredients and fingerprint analysis. None. The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media according to the requirement on exclusive licence of the publication. The data of this article could be shared within six months after the trial complete via the Medroad Cloud Electronic Data Capture System (http://cloud.medroad.cn/). Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ368, m1091 Psychological status of healthcare workers during the civil war and COVID-19 pandemic: A cross-sectional study The Novel Coronavirus Disease (COVID-19) and Its Impact on Cardiovascular Disease Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial Active case finding with case management: the key to tackling the COVID-19 pandemic National Health Commission of the People's Republic of China (NHC-China) and National Administration of Traditional Chinese Medicine of the People's Republic of China Utilizing drug repurposing against COVID-19 -Efficacy, limitations, and challenges.Life Sci259, 118275 Clinical Characteristics and Prognosis of 244 Cardiovascular Patients Suffering from Coronavirus Disease in Wuhan Research priorities in traditional Chinese medicine Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.BMJ369, m1849 Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19 The State Council Information Office of the People's Republic of China.Fighting Covid-19: China in Action The rush to create a covid-19 vaccine may do more harm than good. BMJ370, m3209 A novel coronavirus outbreak of global health concern Ethical Considerations for COVID-19 Vaccine Trials in Correctional Facilities Sleep Disturbance and Psychological Profiles of Medical Staff and Non-Medical Staff during the Early Outbreak of COVID-19 in Hubei Province Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19 Radiomics Analysis of Computed Tomography helps predict poor prognostic outcome in COVID-19 Efficacy of HuoxiangZhengqi dropping pills and LianhuaQingwen granules in treatment of COVID-19: A randomized controlled trial Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis. Pharmacol Res160,105056 Emerging strategies on in silico drug development against COVID-19: challenges and opportunities Total bilirubin Creatine kinase Blood sodium Blood chlorine Blood sedimentation Chest CT parameters-Median(IQR) score of ground glass area 16 Li Li, Benliang Zou, Ning Wang, Shihuan Tang, Min Li, Xunlu Yin, Hao Wang, Chuanzhou Yang, Chunyu Gao, Liying Wang, Yongli Dong, Ming Chen, Lu Zhang, Xu Wei contributed to the data recording.Yang Zhao, Qiaoning Yang, RuiLi,YingjueJia,Yu Dong carried out the second level quality control. Hongjun Yang carried out the third level quality control and Yanping Wang contributed to the management of the trial. JL contributed to the writing on this paper and in charge of the trial management during this study. WY contributed to the data cleaning and statistical analysis. YL contributed to the result analysis and modified the study report. CL contributed to the data collection organization on-site in Wuhan Jinyint Hospital and carried out the first level quality control. LR contributed to the organization in Wuhan Jinyintan LG contributed to finalize the structure of this paper. LH organized the research group and contributed to the overall designing and management of this trial for the corresponding authorship.